Heart failure & cardiomyopathies
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies
Pooled result · All-cause death (ACD)Result — go to the resultRelative risk 0.59 95% CI 0.48–0.72Authors' conclusion
The administration of SGLT2i proved to be well tolerated in patients with CA. Randomized controlled trials are urgently needed to confirm the prognostic improvement associated with their use in this clinical setting.
Study context
- Population
- Patients with cardiac amyloidosis (CA)
- Participants
- 19,227 patients13 observational studies
- Comparison
- Pooled risk ratio (RR) of all-cause death (ACD) and hospitalization due to worsening heart failure (WHF) between treatment- and control-groups
- Outcome
- All-cause death (ACD)
Pooled result
As reported in the abstract
Relative risk
0.59
95% CI 0.48–0.72
SGLT2i-groupvs control-groups
RR 0.59 (95% CI 0.48–0.72)
Further pooled results
| Outcome | Median difference (95% CI) | |
|---|---|---|
| NT-proBNP levelsReduction with SGLT2i | −525.54 (−718.09 to −332.98) | |
| −1000−5000500Difference (linear scale) |
Hospitalization due to worsening heart failure (WHF)
- No significant association with WHF
Safety
- Cumulative prevalence of adverse events (AEs) in the SGLT2i-group
- 8% · cumulative prevalence · 95% CI 2–17
- Drug discontinuation (DD) in the SGLT2i-group
- 4% · cumulative prevalence · 95% CI 1–7
- Cumulative prevalence of adverse events (AEs) in the SGLT2i-group: nine studies, 603 patients
- Drug discontinuation (DD) in the SGLT2i-group: nine studies, 603 patients
Original publication
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies. Eur Heart J Cardiovasc Pharmacother. Published 17 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →